John Pagel

16PUBLICATIONS
120CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedHaematological tumoursMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Dec 03, 2024
Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.

Jeff P Sharman, Miklos Egyed, Wojciech Jurczak

|Sep 19, 2024
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian

|Jun 03, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.

Michelle Y Zhang, Megan Othus, Kerry McMillen

|Apr 01, 2024
Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203.

Mary-Elizabeth Percival, Michelle Zhang, Megan Othus

|Nov 08, 2023
Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors.

Johnnie J Orozco, Phuong T Vo, Ted A Gooley

|Nov 07, 2023
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.

Guillermo Garcia-Manero, Nikolai A Podoltsev, Megan Othus

Pageof 3

Frequent Collaborators

4 joint publications

Paolo Ghia

4 joint publications

Ian W Flinn

3 joint publications

Damian J Green

3 joint publications

William G Wierda